Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 4:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Anti-Influenza Vaccine Placebo Clear all
Completed Phase 2 Interventional Results available

Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A

NCT03315104
View directory record Official record
Conditions
Influenza A H3N2, Influenza A H1N1
Interventions
FLU-IGIV, Placebo for FLU-IGIV
Biological · Other
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Sep 30, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants

NCT04471038
View directory record Official record
Conditions
Influenza Type A, Influenza Type B, Influenza
Interventions
SAB-176, Normal Saline
Biological · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 30, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza

NCT02287467
View directory record Official record
Conditions
Influenza A, Influenza B
Interventions
Intravenous hyperimmune immunoglobulin (IVIG), Placebo for IVIG
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
17
States / cities
San Diego, California • Denver, Colorado • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 30, 2026, 4:32 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza

NCT02927431
View directory record Official record
Conditions
Virus Diseases
Interventions
Danirixin 15 mg FBE, Danirixin 50 mg FBE, Placebo, Oseltamivir 75 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Stamford, Connecticut • Council Bluffs, Iowa • Natchitoches, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Sep 30, 2026, 4:32 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo

NCT06435936
View directory record Official record
Conditions
PHA1A
Interventions
Single Ascending Dose of SAB-176, Single Ascending Dose of Placebo
Drug
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Sep 30, 2026, 4:32 AM EDT
Completed Phase 1 Interventional

PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

NCT02544880
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Interventions
Tadalafil, Anti-MUC1 Vaccine, Anti-Influenza Vaccine, Tadalafil Placebo, Anti-MUC1 Vaccine Placebo, Standard of Care Treatment, Anti-Influenza Vaccine Placebo
Drug · Biological · Other
Lead sponsor
Donald T. Weed, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Sep 30, 2026, 4:32 AM EDT
Completed Phase 1 Interventional

Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)

NCT02008578
View directory record Official record
Conditions
Influenza
Interventions
Intravenous hyperimmune immunoglobulin (Flu-IVIG), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
11
States / cities
San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Sep 30, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Anti-Influenza Virus Monoclonal Antibody to Treat Influenza

NCT01390025
View directory record Official record
Conditions
Influenza, Human
Interventions
TCN-032, Placebo
Biological
Lead sponsor
Theraclone Sciences, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2012 · Synced Sep 30, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza

NCT01231620
View directory record Official record
Conditions
Influenza, Human
Interventions
Zanamivir, Placebo to match zanamivir, Oseltamivir, Placebo to match oseltamivir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
16 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Sep 30, 2026, 4:32 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics Study of Human Monoclonal Antibody (FGI-101-1A6)

NCT01299142
View directory record Official record
Conditions
Influenza
Interventions
FGI-101-1A6
Drug
Lead sponsor
Functional Genetics Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2011 · Synced Sep 30, 2026, 4:32 AM EDT